San Diego, United States
Creyon Bio, founded in 2019, is at the forefront of RNA drug design, operating within the Biotechnology and Life Sciences industries. Headquartered in the United States, Creyon aims to transform the therapeutic landscape with its AI-driven approach to crafting tissue-specific, RNA-targeted nucleic acid therapies.
Focusing primarily on conditions such as neuromuscular, central nervous system (CNS), and immunology disorders, Creyon targets areas where existing RNA therapies encounter barriers in delivery and tolerability. The company's mission underscores a commitment to advancing RNA medicines through precise delivery and a profound grasp of tissue biology, thereby enhancing patient outcomes and quality of life.
Backed by a $40.00M Series A investment in March 2022, Creyon's investors include reputable entities such as Lux Capital, Casdin Capital, Alexandria Venture Investments, BioBrit, and DCVC Bio. With ambitions to lead the paradigm shift toward tissue-aware and patient-centered RNA treatments, Creyon is well-positioned to redefine the future of RNA drug development.
